Skip to main content

Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs

Written by Customer Service on . Posted in Public Companies.

– Details of New Paltusotine Tablet Formulation to be Unveiled –
– Preclinical Evidence Supporting Programs in Congenital Hyperinsulinism and Congenital Adrenal Hyperplasia and Cushing’s Disease Selected for Oral and Late-breaking Presentations –SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) —  Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced upcoming oral and poster presentations at the Endocrine Society’s annual ENDO 2021 congress. In addition to a poster summarizing the company’s previously announced ACROBAT Phase 2 results of paltusotine for the treatment of acromegaly, Crinetics will provide details of the improved tablet formulation of paltusotine that the company plans to advance into Phase 3 studies. Preclinical evidence supporting the company’s development of its selective somatostatin receptor type 5 (SST5) agonist, CRN04777, for the treatment of congenital hyperinsulinism was selected for a late-breaking e-poster presentation. An oral presentation will also be given on the preclinical studies of CRN04894, the company’s lead adrenocorticotropic hormone (ACTH) antagonist for the treatment of diseases associated with excess ACTH such as congenital adrenal hyperplasia (CAH) and Cushing’s disease.The poster and oral presentations will be made available on the Crinetics website following the conclusion of the congress. For ENDO attendees, Crinetics staff will also be available to address questions and discuss pipeline programs in the virtual exhibit hall.March 20, 2021, 11:00 a.m. eastern time
Session P15
Bench to Bedside: Novel Mechanisms in Diabetes and MetabolismSelective Somatostatin 5 (SST5) and Somatostatin 2 (SST2) Nonpeptide Agonists Potently Suppress Glucose- and Tolbutamide-Stimulated Dynamic Insulin Secretion from Isolated Human Islets
Session P30
Clinical Trials and Study Updates in Neuroendocrinology and PituitaryPharmacokinetics and Safety of an Improved Oral Formulation of Paltusotine, a Selective, Nonpeptide Somatostatin Receptor 2 (SST2) Agonist for the Treatment of AcromegalySafety and Efficacy of Switching Injected Peptide Long-Acting Somatostatin Receptor Ligands to Once Daily Oral Paltusotine: ACROBAT Edge Phase 2 StudyMarch 21, 2021 at 2:00 p.m. eastern time
Session OR03
Wide Spectrum of Translational Adrenal ResearchEffects of CRN04894, a Nonpeptide Orally Bioavailable ACTH Antagonist, on Corticosterone in Rodent Models of ACTH Excess
About Crinetics PharmaceuticalsCrinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, paltusotine (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 (SST2) agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 program in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. The company is also developing CRN04777, an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as CRN04894, an investigational, oral, nonpeptide ACTH antagonist for the treatment of Cushing’s disease, congenital adrenal hyperplasia, and other diseases of excess ACTH. All of the company’s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company. For more information, please visit crinetics.com.Contacts:
Marc Wilson
Chief Financial Officer
IR@crinetics.com
(858) 450-6464Investors / Media:
Corey Davis
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
(212) 915-2577Aline Sherwood
Scienta Communications
asherwood@scientapr.com
(312) 238-8957

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.